Company News

Leading international experts advise Oxford Vacmedix on development programme Oxford, UK – 31st January 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announces today the first meeting of its Scientific Advisory Council. World-class experts gathered to guide the research and preclinical development programmes of the company […]

Appointment brings further expertise in immunology and pharmaceutical development to Oxford Vacmedix Oxford 12th October 2018; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that Professor Xiao-Ning Xu will join the company’s Scientific Advisory Council. Professor Xu is an immunologist who was previously a research leader at the

World-class immunologist to advise Oxford Vacmedix on development of novel cancer vaccines. Oxford Vacmedix, a UK-based biopharma company focused on the development of cancer vaccines, announced today that Professor Sir Andrew McMichael will join the company’s Scientific Advisory Council. Sir Andrew is an immunologist, Emeritus Professor, former Professor of Molecular Medicine, and previously Director of

Directors join Oxford Vacmedix from Myongji Hospital Group and Series A investors Cancer ROP in South Korea and Mr Jin from China. Oxford Vacmedix UK Limited (OVM), the UK-­‐based biopharma company focused on the development of cancer vaccines, confirmed today the appointment of new Directors to the Board. These new appointments follow the successful Series

June 2018 – Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium View in PDF

Oxford Vacmedix UK Limited (OVM) has completed its Series A financing round of $12.5m (£9m). Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors, including Cancer ROP, a leading